Whitfield LR - Search Results

1

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.

Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ. Posvar EL, et al. Among authors: whitfield lr. J Clin Pharmacol. 1996 Aug;36(8):728-31. doi: 10.1002/j.1552-4604.1996.tb04242.x. J Clin Pharmacol. 1996. PMID: 8877677 Clinical Trial.

2

Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase.

Whitfield LR, Stern RH, Sedman AJ, Abel R, Gibson DM. Whitfield LR, et al. Eur J Drug Metab Pharmacokinet. 2000 Apr-Jun;25(2):97-101. doi: 10.1007/BF03190074. Eur J Drug Metab Pharmacokinet. 2000. PMID: 11112089 Clinical Trial.

3

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.

Radulovic LL, Cilla DD, Posvar EL, Sedman AJ, Whitfield LR. Radulovic LL, et al. Among authors: whitfield lr. J Clin Pharmacol. 1995 Oct;35(10):990-4. doi: 10.1002/j.1552-4604.1995.tb04015.x. J Clin Pharmacol. 1995. PMID: 8568017 Clinical Trial.

4

Effect of age and gender on pharmacokinetics of atorvastatin in humans.

Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR. Gibson DM, et al. Among authors: whitfield lr. J Clin Pharmacol. 1996 Mar;36(3):242-6. doi: 10.1002/j.1552-4604.1996.tb04194.x. J Clin Pharmacol. 1996. PMID: 8690818 Clinical Trial.

5

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening.

Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Cilla DD Jr, et al. Among authors: whitfield lr. J Clin Pharmacol. 1996 Jul;36(7):604-9. doi: 10.1002/j.1552-4604.1996.tb04224.x. J Clin Pharmacol. 1996. PMID: 8844442 Clinical Trial.

6

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.

Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Cilla DD Jr, et al. Among authors: whitfield lr. Clin Pharmacol Ther. 1996 Dec;60(6):687-95. doi: 10.1016/S0009-9236(96)90218-0. Clin Pharmacol Ther. 1996. PMID: 8988072 Clinical Trial.

7

Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction.

Stern RH, Gibson DM, Whitfield LR. Stern RH, et al. Among authors: whitfield lr. Eur J Clin Pharmacol. 1998 Feb;53(6):475-8. doi: 10.1007/s002280050409. Eur J Clin Pharmacol. 1998. PMID: 9551707 Clinical Trial.

8

Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.

Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D. Whitfield LR, et al. J Clin Pharmacol. 2011 Mar;51(3):378-88. doi: 10.1177/0091270010366446. Epub 2010 Apr 22. J Clin Pharmacol. 2011. PMID: 20413454 Clinical Trial.

9

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.

Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. Boyd RA, et al. J Clin Pharmacol. 2000 Jan;40(1):91-8. doi: 10.1177/00912700022008612. J Clin Pharmacol. 2000. PMID: 10631627 Clinical Trial.

10

Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices.

Shum YY, Huang N, Walter G, Black A, Sekerke C, Chang T, Whitfield LR. Shum YY, et al. Among authors: whitfield lr. Ther Drug Monit. 1998 Feb;20(1):41-9. doi: 10.1097/00007691-199802000-00008. Ther Drug Monit. 1998. PMID: 9485553

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters